Is Avotermin Safe and Effective Treatment for Scar Improvement in Healthy Males and Females? by Leon, Maria Vera
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2015
Is Avotermin Safe and Effective Treatment for Scar
Improvement in Healthy Males and Females?
Maria Vera Leon
Philadelphia College of Osteopathic Medicine, Mariaver@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Tissues Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Leon, Maria Vera, "Is Avotermin Safe and Effective Treatment for Scar Improvement in Healthy Males and Females?" (2015). PCOM
Physician Assistant Studies Student Scholarship. 234.
http://digitalcommons.pcom.edu/pa_systematic_reviews/234
  
 
 
 
 
 
Is Avotermin safe and effective treatment for scar improvement in 
healthy males and females? 
 
 
 
 
 
 
 
Maria Vera Leon, PA-S 
 
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
 
In Partial Fulfillment of the Requirements For 
 
The Degree of Master of Science 
 
In 
 
Health Science – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
 
 
December 20, 2014 
 
 
 
 
 
 
 
 
ABSTRACT    
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
avotermin is a safe and effective treatment for scar improvement in healthy males and females.  
  
STUDY DESIGN: Systemic review of three primary research studies published in the English 
language, one published in 2010 and the other two in 2011. 
 
DATA SOURCES: Two randomized placebo controlled phase II trials and one double blind 
within patient placebo controlled phase II clinical trial, analyzed and compared the effectiveness 
in the administration of avotermin against a placebo in the improvement and diminution of scars. 
All articles were found using Pubmed and Cochrane Library EBM databases. 
 
OUTCOMES MEASURED: Each of the studies measured the effectiveness of avotermin to 
improve appearance and reduce size of scar after surgery procedure. In order to determine 
reduction of size and improvement of appearance total scar score (ToScar) derived from a visual 
analogue score (VAS) was used pre and post intervention. So, et al. also used Global scar 
comparison scale, silicone molds evaluated with PRIMOS scale and histological evaluation of 
tissue 
 
RESULTS: The study by Bush et al reported p=0.0031 and p=0.0140 for avotermin 200ng once 
or twice respectively at 12 month and 61% of adverse events in experimental group.  The study 
by McCollum et al reported, RR= 6.4, RRR=540%, ARR: 27% NNT= 4 and p=0.007 at 12 
month. In addition, RRI=-8%, ARI=-1.3% and NNH=-77. Similar results were obtained in the 
study by So K et al which reported p= 0.04 at 12 month and RRI=11%, ARI=5% and NNH=20. 
All studies reported minimal adverse reactions to avotermin in addition to statistical significance 
in favor of the experimental drug avotermin as an effective treatment for scar improvement. 
 
CONCLUSIONS: Based on the congruency of the data analyzed in these trials, avotermin is 
safe and effective for treatment of scar reduction and improvement which warrants the use of the 
drug.  
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INTRODUCTION  
 
Scarring is part of the natural biological healing process of tissue repair after injury to the 
skin that can be cause by a mere accident or surgery.
1  
Regardless of the nature of scar, scarring 
can cause distortion of normal tissue, which can results in psychosocial disturbance associated 
with aesthetics, distress, and disfigurement that usually impacts negatively an individual’s life.2 
This paper appraises two randomized, double blind, within-patient, placebo controlled phase II 
trials and one randomized phase II clinical trial, which will evaluate and compare the 
effectiveness in the administration of avotermin against a placebo in the improvement and 
diminution of scars.   
Scarring is relevant to the Physician Assistant profession in regards to patient’s physical 
and psychological wellbeing, prevalence, treatment options, and cost. Patient’s own discontent 
with aesthetic perception of scar can result in “sleep disturbance, anxiety, depression, and 
disruption of daily activities”2 in addition to “psychosocial sequelae including development of 
post-traumatic stress reactions, loss of self-esteem, and stigmatization leading to diminished 
quality of life.”2 Therefore, eliciting health care provider’s interest to find adequate treatment or 
referrals for proper management of scars in individuals who potentially suffer from secondary 
somatic and psychological symptoms. It is estimated that each year approximately 100 million 
individuals acquire scars due to trauma or surgery, resulting in 55 million elective operations and 
25 million operations after trauma.
2
 There is a wide spectrum of scar types ranging from fine 
lines to hypertrophic ones. Depending on scar type, treatment may comprise invasive methods 
involving steroid injections and surgery or conservative methods using compression therapy, 
topical silicone gel or photodynamic therapy.
3 
The exact number of patients undergoing scar 
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revision surgery within the last few years is not currently available; however according to the 
American Society of  
Plastic Surgeons report of 2009, there were 171,237 scar revision procedures done in the United 
States in that year.
4
 Exact annual cost for scar revision surgery is variable and depends on 
surgeon’s fee, hospitals costs, anesthesia fees, and region in the United States in which the 
surgery is performed at.
5
  
Despite all the available invasive and conservative alternative treatments for scar 
reduction, there is no individual intervention that completely eliminates scars or cause scars to 
disappear. Recent studies introduced transforming growth factorTGF also known as 
avotermin as an alternative prophylactic treatment for scarring, due to its vital role in suppression 
of scar formation, relative safety, efficacy, and tolerability upon administration.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not avotermin is 
safe and effective treatment for scar improvement in healthy males and females.  
METHODS 
Articles utilized in this review were considered based on a number of criteria. A literature 
search using PubMed and Cochrane Database with activated filters for Randomized Controlled 
Trial, humans, adults: 19-85 years was applied and yield two randomized, double blind, within-
patient, placebo controlled phase II trials and one randomized phase II clinical trial. All articles 
chosen were obtained through PubMed and were published in the English language, between 
2010 and 2011. Inclusion of articles were considered based on relevance and outcomes important 
to the patient and physician assistant practice.  The studies excluded were articles published 
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before 2000 and those that included individuals younger than 18 years old. The key words used 
were scar improvement, avotermin, Transforming growth factor   
Selection criteria for studies included the following: The population considered 
comprised healthy nonblack patients older than 18 years of age that were undergoing a surgical 
procedure. Two of the studies used avotermin 200ng/100 ul/linear centimeter of wound margin 
and one used 500ng/100ul/cm as the main intervention treatment. Comparisons included within 
patient controlled placebo group in order to minimized confounding factors affecting scarring. 
Results were based on ToScar and Visual Analog Scale score (VAS).  
Two of the studies reported statistics using p values and one contained dichotomous data, 
which was used to calculate Absolute Risk Reduction (ARR), Relative Risk Reduction (RRR), 
and Numbers Needed to Treat (NNT). Table 1, depicted demographics of the chosen articles  
TABLE 1: Demographics & Characteristics of included studies  
Study Type #pt Age  Inclusion criteria Exclusion criteria W/D Interventions 
 
Bush et 
al
6 
(2010) 
 
RCT 71 18-45 
y.o 
men 
Healthy individual 
(18-45 years) 
Caucasian  
BMI between 15 and 
55kg/m2  
 
Afro-Caribbean individuals, 
those with  general medical 
conditions, skin disorders, 
taking medications affecting 
wound healing,  
hx of hypertrophic or keloid 
scaring, allergies  
and tattoos in biopsy area 
13 Avotermin 200 
mg/100ul 
(transforming 
growth factor 
beta-3) VS. 
Within patient 
controlled placebo  
McColl
um et 
al
7
 
(2011) 
 
RCT 156 18 -
85 y.o 
men 
& 
wome
n  
bilateral removal of 
varicose veins by 
sapheno-femoral 
ligation and long 
saphenous vein 
stripping BMI of 15–
35 kg/m2 
Subjects with hx of prior 
surgical treatment for 
varicose veins, suffered 
from bleeding disorders, 
impaired wound healing,  
existing scars within 3 cm 
of potential trial wounds and 
oral corticosteroid therapy 
4 Avotermin 500 ng 
per 100 ul VS. 
Within patient 
controlled placebo  
 
 
So K et 
al
8
 
(2011) 
 
RCT 60 18-85 
y.o 
men 
and 
wome
n 
Subjects with a  
mature, stabilized, 
linear scar that was ≥l 
5 cm in length, and it 
was ≥ 12 month old 
scar 
BMI of 15 to 35kg/m2 
Patients with scars distorted 
by joints or anatomical 
structures 
Subjects with a history of 
keloid scarring 
Subjects with medical 
conditions that could impair 
wound healing 
5 Avotermin (200 
ng/100ul linear 
cm wound 
margin) VS. 
Within patient 
controlled placebo  
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OUTCOMES MEASURED  
The outcomes measured in these studies were those relevant to Patient Oriented Evidence 
that Matters (POEMs) as is the case of scar appearance, improvement, and size reduction. 
Efficacy assessment outcomes were primarily measured by using Total Scar Score derived from 
the Visual Analog Scale (VAS) which is “a photograph-based scale derived from evaluating 
standardized digital photographs in 4 dimensions (pigmentation, vascularity, acceptability, and 
observer comfort) plus contour.”9 All selected studies used the VAS to assess scar appearance, 
but differed in the time period assigned for evaluation. Bush, et al. and So, et al used monthly 
measurement assessments based on a 12 month period
 6, 8
 and McCollum, et al used follow up 
periods for assessment at 6 weeks, 3, 5, 7 and 12 month.
7  
Scar appearance was evaluated by a 
lay panel and investigators. Selection of lay panel members was determined based on their 
ability to consistently score scars according to VAS training.
6, 7, 8  
Standardize values for VAS 
included 0 mm up to 100mm with 0 mm being consistent with normal skin and 100 mm being 
poorest outcome according to the scale. 
6, 7, 8 
  Calculation of ToScar used the mean VAS values 
from follow up assessment measurements.
7, 8
 In addition to the ToScar score derived from VAS 
values, So, et al. also used Global Scar Comparison, silicon molds which were analyzed by the 
PRIMOS system and histological examination of sample tissue excised at month 7 was also 
done. 
8
  
Safety outcome measurements in Bush, et al and So, et al. included adverse events, local 
tolerability (i.e pruritis, pain and burning sensation), and observation of erythema, edema and 
exudate, blood analysis for immunogenicity, clinical chemistry and urinalysis. 
6, 8  
Bush, et al. 
also included pulse, blood pressure measurements and electrocardiogram test for assessment of 
safety.
6 
Safety outcomes measurements in McCollum, et al. included urinalysis, hematologic 
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chemistry and blood samples to measure anti-TGF-b3 before and after administration of 
avotermin.
7 
 
RESULTS  
This systemic review evaluates two double blind within patient placebo controlled phase 
II clinical trial and one randomized phase II clinical trial versus placebo. All three clinical trials 
that are being reviewed use avotermin versus placebo as prophylactic treatment for scar 
reduction.  McCollum, et al presented dichotomous data which was used to assess efficacy and 
safety. Bush, et al and So, et al presented statistical data as p values which were consider 
significant if p<0.050; however for safety, dichotomous data was provided and used to calculate, 
Relative Risk Increase (RRI),  Absolute Risk Increase (ARI), and Number Needed to Harm 
(NNH). Participants in all three studies received written information and consented to participate 
in each trial, all of which were approved by regional independent ethics committees. All studies 
were conducted following the Declaration of Helsinki and either the International Conference on 
Harmonisation: Harmonised Tripartite Guidelines for Good Clinical Practice or International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. All studies used intention to treat (ITT) last observation carried forward (LOCF) in 
efficacy analysis and safety population was determined as all patients who received 
administration of avotermin and were evaluated at least once.
6, 7, 8
 
Bush, et al (2010) study investigate efficacy of different avotermin doses that was either 
administered as a single or double dose in individuals receiving incisional wounds.
6
 Individuals 
of Afro-Caribbean descent were excluded due to high susceptibility for keloid scaring. Likewise, 
those with history of hypertrophic or keloid scaring, significant allergies and tattoos in biopsy 
areas. Additionally to those with medical conditions, skin disorders or taking medications that 
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might affect wound healing 
6 
A homogeneous population of Caucasian males between 18 and 45 
years was included in the study.
6
 Study was conducted between October 2003 and August 2005, 
71 individuals were recruited and randomly allocated to treatment dose administration groups  
based on a computer generated code.
6
  
Informations from Independent external scar assessment panel’s (IESAP) visual analog 
scale (VAS) score reported wounds treated with avotermin at 200ng/100ul/linear cm 
administered once (mean difference= 0.75 cm and p=0.0031) or twice (mean difference 0.74 cm, 
p=0.0140) were better in reducing scarring than those treated with placebo since month 1 to 
month 12.
6
 In addition, there was a 64% and 77% scar improvement compared to placebo for use 
200ng avotermin once or twice respectively.
6
 (Table 2)  
Table 2: Placebo vs Avotermin administer once (x1) or twice (x2) comparison at month 12 
Treatment  Mean (SD) Avotermin 
# wound 
pairs (%) 
Control 
# wound 
pairs (%) 
P value avotermin % 
improvement 
 
Placebo vs avotermin 200ng x 1 0.75 (1.266)   20 (65%)     11 (35%)      0.0031 64% 
Placebo vs avotermin 200ng x 2 0.74 (1.573)    23 (74%)       8 (26%)       0.0140 77% 
* SD, standard deviation; x1once; x2 twice 
 
Independent external scar assessment panel (IESAP) scar ranking reported approximately 65% 
preference of scars treated with avotermin 200mg once or twice versus placebo which reported 
about 31% preference; except for avotermin 200ng (twice) with p=0.0071, no other statistical 
significance data was reported.
6 
(table 3)
  
Table 3: IESAP efficacy findings at month 12  
Treatment  IESAP VAS response rate. p 
(%favor of avotermin; %favor of 
placebo) 
IESAP ranking of scar. p (% 
favor of avotermin;% favor of 
placebo) 
Placebo vs avotermin 200ng x 1 NS (65%:35%) NS (62%:31%) 
Placebo vs avotermin 200ng x 2 0.0071 (74%:26%) NS (60%:33%) 
*VAS, visual analog scale; SD, standard deviation; NS, no significant p value; x1once; x2 twice 
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Bush, et al. report 61% systemic adverse events in experimental group, however adverse events 
at wound sites were similar for avotermin and controls (Table 6). Erythema, edema, exudate and 
thickening were equally frequent with avotermin and placebo, suggesting normal wound 
healing.
6
  There were no deaths, withdrawals or discontinues from study due to adverse effects.
 
McCollum, et al (2011) study assessed efficacy of single intradermal injection in near 
wound margins following varicose vein removal.
7 
Individuals with prior varicose veins surgery 
were excluded, in addition to those suffering from bleeding disorders, had impaired wound 
healing or an existing scar within 3 cm of potential trial wounds or were taking a corticosteroid 
therapy. 
7 
All considerations for exclusion were made to avoid potential confounding effects with 
previous scar or inability to achieve healing of scar of interest.  A heterogeneous population of 
non-African Caribbean descent between 18 and 85 years with BMI of 15-35kg/m
2
 who 
undergone bilateral saphenofemoral ligation and stripping were included in the study.
 7 
Study 
was conducted between November 2006 and January 2009; 156 individuals were recruited and 
randomly allocated to treatment dose groups.
7
  
Lay panel ToScar analysis reported “avotermin 500ng/100ul per linear cm (500-ng dose) 
compared with placebo (mean ToScar difference 16.49 mm; n=40, p=0.036)” Lower doses were 
not statistically significant and p values were not reported.
7 
Lay panel VAS score reported steady 
improvement of scar appearance based on VAS scores at all times from week 6 to month 12 for 
both avotermin and placebo; however avotermin 500-ng had better results compared to placebo.
7 
Lay panel ranking reported significant improvement that warrants used of avotermin vs placebo. 
Based on the data reported in the study, Relative Risk (RR) determined 6.4 times higher risk of 
having scar improvement compared to placebo. Relative Risk Reduction (RRR) was 540%, 
Absolute Risk Reduction (ARR) was 27% in scar reduction rate. NNT was calculated as four, 
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meaning that for every four patients undergoing surgical procedures that receive 500ng/100ul/cm 
of avotermin, one more patient will have better scar results after procedure compared to control 
(Table 4).  
Table 4: Efficacy of 500-ng dose avotermin in prophylactic treatment of scarring12 month period 
 CER* EER* RR* RRR* ARR* NNT* P value 
LayPanel ranking 5% 32% 6.4 540% 27% 4 P=0.007  
*CER=Control Event Rate, EER=Experimental Event Rate, ARR=Absolute Risk Reduction, 
RRR= Relative Risk Reduction, NNT=Number Needed to Treat 
 
McCollum, et al. did not report a significant site specific adverse events between 
avotermin (14.1%) and placebo (15.4%). Adverse events at wound sites were similar for 
avotermin and controls, wound infection was as frequent with avotermin as with placebo. 
Relative Risk Increase (RRI) was -8%, Absolute Risk Increase (ARI) -1.3%, and NNH was -77. 
Therefore, for every 77 patients receiving avotermin, one fewer would experience site-specific 
adverse events, compared to placebo (Table 6). Adverse events that were considered related to 
treatment include, hypotension and slow bleed from wound area, 58.3% experienced headaches. 
One patient died due to cerebral hemorrhage but it was discarded that it was the result of 
treatment; however, there were no withdrawals or discontinues.
7  
So, et al study evaluated efficacy of intradermal avotermin in patients undergoing scar 
revision surgery.
8
 Excluded individuals included those with prior history of keloid scarring or 
impair wound healing, in addition to those with distorted scars in joints or anatomical structures 
of interest of study.
8 
A heterogeneous population of individuals who had a qualifying scar and 
were older than 18 and younger than 85 years with BMI between 15 to 35 kg/m
2 
were included.
8
 
Study was conducted between May 2006 and September 2008; 60 individuals were recruited and 
randomly allocated to treatment dose groups.
8  
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Lay panel combine analysis of both experimental groups to determined ToScar score 
which “showed that avotermin treatment resulted in a statistically significant improvement in 
total scar score of 21.93 mm compared with placebo (p=0.04; 95 percent confidence interval, 1.2 
to 42.6 mm).”8 Lay panel VAS score reported avotermin treated scars had a greater improvement 
in appearance compared to placebo, the mean VAS score at month 12 for avotermin was -
17.21mm and -12.90mm for placebo treated scars.
8 
(Table 5) Profilometry results showed a 
change from baseline avotermin 12 month, -96.41mm
2 
 versus placebo -53.98 mm
2 
, resulting in 
a difference of 27.52 and p=0.03.
8
 (Table 5) Histological samples concluded that scar treated 
with avotermin resemble normal skin better than placebo.  
Table 5. VAS and Profilometry Evaluation of avotermin efficacy at 12 months  
VAS score  Avotermin 200ng/100ul Placebo P-value 
Change from baseline at 12months -17.21mm
 
-12.90mm P=0.04 
Profilometry results  Avotermin Placebo  
Change from baseline at 12months -94.41 mm
2 
-53.98 mm
2
 P=0.03 
 
So, et al. did not report a significant site specific adverse events between avotermin 
(52%) and placebo (47%) or wound complications (pain and burning) avotermin (38%) versus 
placebo (37%). Adverse events at wound sites were similar for avotermin and controls. Erythema 
was more frequent with avotermin than with placebo, but it was transient and deemed to be 
consistent with normal wound healing. Relative Risk Increase (RRI) was 11%, Absolute Risk 
Increase (ARI) 5%, and NNH was 20 meaning that for every 20 patients receiving avotermin, 
one additional will experience site specific adverse events, compared to placebo. 12% of patient 
reported headache. There were no deaths, withdrawals, or discontinues accredited to adverse 
events caused by avotermin.
8 
Table 6. Incidence of adverse events in avotermin and placebo groups  
 Avotermin Placebo RRI ARI NNH 
Bush, et al. 23/38=61%     
McCollum, et al. 22/156=14.1% 24/156=15.4% -8% -1.3% -77 
So, et al. 31/60=52% 28/60=47% 11% 5% 20 
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*RRI = Relative Risk Increase, ARI = Absolute Risk Increase, NNH = Number Needed to Harm 
DISCUSSION 
Avotermin is one of the Transforming Growth Factor that belong to the family of 
proteins that are known to play a vital role in wound healing and scar formation.
8
 Studies 
evaluated in this review demonstrate the efficacy and safety of avotermin in the use of 
prophylactic prevention of scar formation. This innovative drug is not found to be approved in 
the United States thus far, but currently it is under investigation in the United Kingdom.  
Studies evaluated in this review were compliant with validity, as all randomly allocated 
treatment in a concealed manner, all participants, investigators and assessor were blinded, and 
follow up for patients was long enough to monitor changes in scar. All three studies analyzed 
showed a superior improvement in scar reduction with the use of avotermin compared to the use 
of placebo, in addition, efficacy was subject also to dosage but not frequency. The larger the 
dosage of avotermin use the greater statistical significance reported. 
This review supports the use of avotermin in the treatment of scarring; however there are 
some limitation worth to mention in the studies chosen. Small sample size depict in Bush et al 
with 71 participants and So et al with only 60 participants did not accurately represent the total 
population affected with this problem. Consequently, overestimating or underestimating true 
effects regarding efficacy and safety.  McCollum et al had a larger population with 156 
individuals which better represent and demonstrate the outcomes of general population.  
CONCLUSIONS  
 Based on this systematic review and the data presented by previous mentioned studies, 
avotermin (Transforming Growth Factor is a safe and effective treatment for prophylactic 
prevention of scar formation following a surgical procedure. Studies evaluated reported 
significant statistical values that warrant the use of avotermin for scar prevention. Evidence also 
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prove that avotermin is safe to use since most of the adverse side effects were also present in 
placebo group and were deemed to be part of the natural healing process of a wound.  
Noting that the population tested in the three trials was very similar and excluded Afro-
Caribbean individuals, future studies should incorporate individuals from black descend to 
determine the efficacy of avotermin in a diverse population. In addition, based on the data 
reported, it appears avotermin use at greater doses yield more effective and valuable results in 
scar appearance. Forthcoming research should augment the dose of avotermin supplementation 
to potentially assess greater efficacy. It will also be of interest if continuing investigations assess 
the efficacy of avotermin in different vehicles such as topical products versus parental ones. 
Further investigation would benefit from employing a larger study group that addresses a 
more diverse population with similar wound location and a narrower and similar age range in 
order to avoid masking true intervention effects.  
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